Michael Grissinger

Michael Grissinger is currently Chairman at Kira Biotech Pty Ltd. since 2020, Director at Atrin Pharmaceuticals LLC since 2018, Independent Director at Aprea Therapeutics, Inc. since 2022, Director at Atriva Therapeutics GmbH since 2020, Director at Envisagenics, Inc., Independent Director at Adicet Bio, Inc. starting 2025, Director at NephroDI Therapeutics, Inc., and Director at AnaCardio AB. Former positions include Independent Director at resTORbio, Inc. from 2018 to 2020, Director at Atrin Pharmaceuticals, Inc., Independent Director at Akari Therapeutics Plc from 2018 to 2024, Member-Management Board at Janssen Pharmaceuticals, Inc., and VP & Head-Pharmaceutical Corporate Development at Johnson & Johnson.
Education includes an undergraduate degree from Juniata College and an MBA from Fox School of Business.